When NICE Reconsiders Itself: What the Lecanemab Deal Reveals About the Price of Slowing Dementia
Two years after rejecting the first drugs shown to delay Alzheimer's disease, the rationing body's methodological reversal exposes how negotiable its own economics can become, and what that might cost the NHS when the next expensive treatment arrives.
By
Distilled Post Editorial Team